inspirator schreef op 1 november 2015 18:41:
[...]
We are pleased to announce our recent acquisition of NovioGendix. MDxHealth will continue the ongoing research, development and commercialization of novel molecular assays for urologic oncology, including SelectMDx for Prostate Cancer test (formerly named Quattro).
The first product that MDxHealth will launch in the European market is SelectMDx for Prostate Cancer. This urine-based test is the successor of the PCA3 test that was identified and developed by professor Dr. Jack A. Schalken and his team at the Radboudumc. In the past years, professor Dr. Schalken and the NovioGendix team developed this next generation non-invasive, ‘liquid biopsy’ test, to more accurately distinguish patients who may harbor clinically significant prostate cancer compared to the PCA3 test. SelectMDx™ can aid in the discrimination between patients with an increased likelihood for high-grade prostate cancer from those with low-grade disease, for whom a prostate biopsy may enable earlier detection.
In November 2014, NovioGendix transferred its routine PCA3 testing services to DDL Diagnostic Laboratory in Rijswijk. However, DDL will no longer provide PCA3 testing services after the 1st of December 2015. Starting on November 1st, 2015, the SelectMDx™ test is available at MDxHealth in Nijmegen.